Edition:
United States

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

8.72USD
11:29am EST
Change (% chg)

$-0.27 (-3.00%)
Prev Close
$8.99
Open
$8.91
Day's High
$8.91
Day's Low
$8.72
Volume
4,593
Avg. Vol
24,002
52-wk High
$14.50
52-wk Low
$6.09

Latest Key Developments (Source: Significant Developments)

Medicinova Inc - On June 1, 2018, Ryan Selhorn Resigned As Chief Financial Officer Of Co
Tuesday, 5 Jun 2018 07:28am EDT 

June 5 (Reuters) - MediciNova Inc ::MEDICINOVA INC - ON JUNE 1, 2018, RYAN SELHORN RESIGNED AS CHIEF FINANCIAL OFFICER OF CO - SEC FILING.MEDICINOVA INC - EFFECTIVE JUNE 1, APPOINTED CARLA REYES OF SIGNATURE ANALYTICS TO SERVE AS CFO AND PRINCIPAL FINANCIAL OFFICER OF CO.  Full Article

Medicinova Announces Pricing Of Underwritten Public Offering
Wednesday, 7 Feb 2018 07:11pm EST 

Feb 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.‍PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4.4 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $9.05 PER SHARE​.  Full Article

MediciNova Announces Proposed Underwritten Public Offering
Wednesday, 7 Feb 2018 04:00pm EST 

Feb 7 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.MEDICINOVA INC - INTENDS TO USE PROCEEDS PRIMARILY TO CONTINUE TO FUND DEVELOPMENT OF ITS MN-166 (IBUDILAST), MN-001 (TIPELUKAST) PROGRAMS​, OTHERS.  Full Article

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Thursday, 7 Dec 2017 06:00pm EST 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 06:00am EDT 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article

Medicinova Inc files for potential mixed ‍​shelf of up to $200 million
Friday, 22 Sep 2017 05:48pm EDT 

Sept 22 (Reuters) - Medicinova Inc :Medicinova Inc files for potential mixed ‍​shelf of up to $200 million - SEC filing.  Full Article

MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence
Tuesday, 19 Sep 2017 06:00am EDT 

Sept 19 (Reuters) - MediciNova Inc :MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence.MediciNova Inc - final results of phase 2 MN-166 study expected by Q1 of 2018.  Full Article

MediciNova to offer off-floor distribution of shares
Monday, 5 Jun 2017 02:53am EDT 

June 5 (Reuters) - MediciNova Inc :* Says it will offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange, from June 13 to June 15.* Offering price will be determined based on the closing share price of the day before the distribution.* Says the limitation for distribution is up to 10,000 shares for each customer.  Full Article

Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence
Monday, 23 Jan 2017 06:00pm EST 

Medicinova Inc : Medicinova announces publication of positive findings on MN-166 (ibudilast) in alcohol dependence . Medicinova Inc - overall, MN-166 (ibudilast) was well tolerated .No severe adverse events and there were no study dropouts directly related to MN-166.  Full Article